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Abstract
Background: Bone microarchitecture is a significant determinant of bone strength. So far, the
assessment of bone microarchitecture has required bone biopsies, limiting its utilization in clinical
practice to one single skeletal site. With the advance of high-resolution imaging techniques, non-
invasive in vivo measurement of bone microarchitecture has recently become possible. This
provides an opportunity to efficiently assess the effects of anti-osteoporotic therapies on bone
microarchitecture. We therefore designed a protocol to investigate the effects of nasal salmon
calcitonin, an inhibitor of osteoclast activity, on bone microarchitecture in postmenopausal women,
comparing weight bearing and non-weight bearing skeletal sites.
Methods: One hundred postmenopausal women will be included in a randomized, placebo-
controlled, double-blind trial comparing the effect of nasal salmon calcitonin (200 UI/day) to
placebo over two years. Bone microarchitecture at the distal radius and distal tibia will be
determined yearly by high-resolution peripheral quantitative computerized tomography (p-QCT)
with a voxel size of 82 µm and an irradiation of less than 5 µSv. Serum markers of bone resorption
and bone formation will be measured every 6 months. Safety and compliance will be assessed.
Primary endpoint is the change in bone microarchitecture; secondary endpoint is the change in
markers of bone turnover.
Hypothesis: The present study should provide new information on the mode of action of nasal
calcitonin. We hypothezise that - compared to placebo - calcitonin impacts on microstructural
parameters, with a possible difference between weight bearing and non-weight bearing bones.
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Background
Osteoporosis is characterized by compromised bone
strength and higher fragility, resulting in an increased frac-
ture risk [1]. The measurement of areal bone mineral den-
sity (BMD) by dual-energy X-ray absorptiometry (DXA) is
the most common way to measure bone mass and to
assess fracture risk. Yet, bone strength is also determined
by bone geometry, bone microarchitecture, bone remod-
elling and intrinsic tissue quality [2]. Thus, it is not sur-
prising that BMD only partially explains the variance of
strength and fracture risk [3]. It has been postulated that
markers of bone remodelling determined in blood or
urine could be independent predictors of fracture risk [4].
Assessment of changes in bone microarchitecture has
been limited, since bone biopsies were necessary to inves-
tigate these parameters in the past. This technique is lim-
ited to a non-weight bearing bone such as the iliac crest.
Today, high-resolution peripheral quantitative computer-
ized tomography (p-QCT) allows an efficient and quanti-
tative evaluation of bone microarchitecture [5,6]. It
determines in three dimensions true volumetric density
(g/cm3), and can directly assess trabecular thicknesses,
trabecular separations, and trabecular number, and also
provides additional geometric variables such as cross-sec-
tional area (CSA) and information on structural pattern
(rod vs. plate structure) with a relatively low irradiation,
high accuracy and precision [7]. P-QCT thus provides a
unique non-invasive opportunity to explore the effects of
diseases on bone microarchitecture and of therapies
intended to halt or reverse these changes [8].
Postmenopausal bone loss and fracture risk are associated
with an imbalance in bone turnover. As a therapeutic
agent, calcitonin binds to specific receptors on the osteo-
clasts and reduces their relative hyperactivity.
The formula of nasal calcitonin is well tolerated. The most
common side effects consist of mild or moderate rhinitis
symptoms, such as nasal congestion and sneezing, or
nasal dryness [9,10]. Rarely, hypersensitivity reactions
may occur.
Prolonged administration of intranasal calcitonin can
prevent postmenopausal bone loss and is also able to
increase trabecular bone mass among patients presenting
established osteoporosis [10,11]. It has been demon-
strated that the prolonged daily administration of 200 IU
intranasal calcitonin inhibits bone resorption, increases
lumbar spine BMD by 1.7%–3.3% after one year, and
reduces vertebral fracture risk [9,12]. Furthermore, spe-
cific modification of bone microstructure was demon-
strated at the distal radius using magnetic resonance
imaging [13].
A possible effect of calcitonin on bone microarchitecture
could be investigated using high-resolution p-QCT. By
assessing structural bone changes, the present study
should thus provide new insights in the mode of action of
nasal calcitonin. We hypothezise that - compared to pla-
cebo - calcitonin improves or maintains microstructural
parameters, with a possible difference between weight
bearing and non-weight bearing bones.
Methods
Study design
This is a monocentric, randomized, placebo-controlled,
double-blind trial over two years, assessing the effects of
nasal calcitonin (200 IU/day) on bone microarchitecture
measured by high resolution p-QCT in postmenopausal
women.
This protocol was initiated by the principal investigator
and has been accepted by the ethics committee of the Uni-
versity Hospitals of Geneva and by the Swiss legislative
authority (Swissmedic). It has been registered in a public
clinical trial data base [ClinicalTrials.gov number
NCT00372099] [14].
End points
Primary efficacy endpoint will be changes in bone struc-
ture and bone microarchitecture evaluated by high resolu-
tion p-QCT in postmenopausal women compared to
placebo during two years.
As a secondary endpoint we will investigate changes in
markers of bone turnover.
Study population
The study population will consist of 100 postmenopausal
women aged 45 to 70 years with a BMD T-Score between
0.0 and -2.49. In- and exclusion criteria are detailed in
Table 1. Given the possible administration of placebo
treatment, women with osteoporosis are excluded from
the study for ethical reasons. Study participants are being
recruited through advertisements in local newspapers;
recruitment has started in January 2007.
Study medication
Participants receive 200 IU calcitonin nasal spray once
daily or the matching placebo spray, provided by Novartis
Pharmaceuticals, Basel, Switzerland. All patients fulfilling
the inclusion/exclusion criteria will be given study medi-
cation. Odds of receiving active treatment or placebo are
1:1. Medication labels comply with the legal requirements
in Switzerland and will be printed in the local language.
The storage conditions for the study drug as well as the
randomization number are specified on the medication
label. No patient identifier is stated on the label.Trials 2008, 9:19 http://www.trialsjournal.com/content/9/1/19
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All patients receive a calcium and vitamin D supplement
(1000 mg/880 UI per day). If the supplement is not toler-
ated, the dose will be reduced or, if necessary, the supple-
ment will be stopped. In this case, the participant may
continue the trial and will be given advice on adequate
dietary calcium intake. A vitamin D supplement of 800
IU/day will then be prescribed during the winter months.
Drug accountability will be noted during visits and at the
completion of the trial. Patients will be asked to return all
unused medication at the end of the study.
Blinding
Patients, investigator staff, persons performing the assess-
ments, and data analysts will remain blind to the identity
of the treatment from the time of randomization until
database lock. The identity of the treatments will be con-
cealed by the use of study drugs that are all identical in
packaging, labeling, schedule of administration, appear-
ance, taste, and odor. Randomization data are kept strictly
confidential until the time of unblinding and will not be
accessible by anyone else involved in the study. Unblind-
ing will only occur in the case of patient emergencies and
at the conclusion of the study.
Study procedures
Potential participants will undergo a screening procedure,
including recording of medical history, physical examina-
tion, blood sampling, and BMD measurements and verte-
bral fracture assessment (VFA) by DXA (Prodigy, GE
Table 1: In- and exclusion criteria
Inclusion criteria
• Women aged 45 to70 years
• Natural or surgical menopause = 1 year
• T-Score between 0.0 and -2.49 (spine or proximal femur – total or femoral neck, measured by DXA)
Exclusion criteria
• Osteoporosis (T-score = -2.5 in spine or proximal femur – total or femoral neck, measured by DXA)
• Severe vertebral fracture, as identified by screening DXA assessment
• Any history of metabolic disease that could affect bone metabolism: hyperparathyroidism, osteogenesis imperfecta, Paget's disease, osteomalacia
• Thyroid disease (if receiving thyroid hormone replacement, the patients must be euthyroid and on a stable dose of thyroid hormone)
• Impaired renal function (estimated creatinine clearance <30 ml/min)
• History of previous or active malignancy of any organ system, treated or untreated, within the past 5 years.
• History of corticosteroid treatments during 6 months or more, daily dosage >5 mg
• BMI < 18 or >30 kg/m2
• Treatments with estrogens, SERMs, tibolone, calcitonin, strontium ranelate, teriparatide or PTH, or oral bisphosphonates in the previous year, if 
duration > 2 weeks. Treatment with iv bisphosphonates or iv calcitonin of any duration in the previous year
Table 2: Visit schedule
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Period Screening Baseline Month 6 Month 12 Month 18 Month 24
Day -7 to -3 0 180 ± 14 360 ± 14 540 ± 14 720 ± 14
Informed consent X
In-/exclusion criteria X X
Medical history X X
Prior/Concomitant medication X X X X X X
Vital signs X X X
Physical examination X X
Adverse events XX X X
DXA X X X
pQCT X X X
Laboratory test X X X
Bone markers X X X X X X
Antibody test X
Study drug dispensing X X X X
Drug accountability XX X X
Study termination sheet XTrials 2008, 9:19 http://www.trialsjournal.com/content/9/1/19
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Healthcare Technologies, Waltham, Wisconsin, USA).
Participants fulfilling the inclusion/exclusion criteria at
screening will be included in the study. During the study,
visits to the trial center will take place every 6 months
(Table 2).
Efficacy assessments
Bone microarchictecture measurements
Bone microarchitecture will be investigated by p-QCT at
baseline and after one and two years. Three-dimensional
high-resolution measurements will be performed at the
distal radius and tibia using an Xtreme CT device (Scanco
Medical AG, Bassersdorf, Switzerland), as described by
others [15]. In brief, the non-dominant limb (or the non-
fractured limb in case of prior fractures) will be scanned at
the standardized locations for human in vivo measure-
ments. The following settings are used: effective energy of
60 kVp, matrix size 1536 × 1536, x-ray tube current 900
µA, slice increment 82 µm. One hundred and ten slices
will be obtained with a voxel size of 82 µm. The effective
dose for one Xtreme CT standard measurement is 3 µSv
per site. Processing of the obtained scans will be done in
accordance with the default protocol of the device. Table
3 lists the assessed bone parameters. In our institution, the
in-vivo coefficient of variation (CV%) for these bone indi-
ces ranges from 0.5 – 1% (vol. densities) to 3 – 5% (TbN).
Quality control is performed on a daily basis.
Bone mineral density measurements
Spine and hip bone mineral density will be measured at
the baseline visit and after one and two years by DXA
(Prodigy, GE Healthcare Technologies, Wisconsin, USA).
The irradiation dose is 7 µSv per examination.
Laboratory test
Fasting serum samples will be obtained from all patients
at the 6-monthly visits. Serum will be stored at -70°C to
allow analysis in batches. Serum total procollagen type 1
amino-terminal propeptide (P1NP), a marker of bone for-
mation, and serum C-terminal telopeptide of type I colla-
gen (β-crosslaps, CTX), a marker of bone resorption, will
both be measured using electrochemiluminescence
immunoassays (Elecsys 2010, Roche Diagnostics). The
intrassay coefficients of variation (CV%) for these meas-
urements are 2.3–3.7% and 1.6–4.7%, respectively. Levels
of serum PTH (7–84) will also be assessed using an elec-
trochemiluminescence immunoassay (CV 4.3–7.1%);
serum 25-hydroxyvitamin D will be determined by a com-
petitive immunoassay (ELISA; CV 5.3–6.7%).
Serum and urine biochemistry as well as hematology will
be measured immediately after blood sampling in the
routine laboratory according to standard procedures. The
titer of calcitonin antibodies will be assessed at end of the
study.
Safety assessments
Safety assessments will include the monitoring and
recording of all adverse events (AEs), including serious
adverse events (SAEs), the regular monitoring of hematol-
ogy, blood chemistry and urine values, regular monitor-
ing of vital signs, physical condition and body weight.
Body height will be measured 6-monthly with a Harpeden
stadiometer (Holtain Ltd, Crymych, UK).
Data management
All original data will be recorded in the patient's source
documentation. Subsequently, anonymized data will be
entered into an electronic database and displayed in the
patient data listings. Tables will display counts of missing
values. Quality control of the data will be done at regular
intervals, using descriptive statistics and visual analyses to
check for inconsistencies and extreme values. Detected
errors will be rectified according to the source data. Data
will be handled in accordance with the good clincal prac-
tice guidelines and applicable local regulations. Data
management and analysis as well as interpretation and
publication of the results remain under the responsibility
of the principal investigator and will be performed by the
study team of the University Hospitals of Geneva.
Statistical methods
Sample size calculation
A total number of 80 patients (40 in the calcitonin group
and 40 in the control group) is necessary to have a statis-
tical power of 80% to detect an expected difference of
3.5% in BV/TV [13]. Due to an expected drop-out rate of
20%, a total of 100 patients should be enrolled.
Statistical analysis
Data will be summarized with respect to demographic
and baseline characteristics, efficacy observations and
Table 3: Parameters of bone microarchitecture
Bone densities
• cortical bone density (Dcort; mgHA/cm3)
• trabecular bone density (Dtrab; mgHA/cm3)
• meta trabecular bone density (Dmeta; mgHA/cm3)
• inner trabecular bone density (Dinn; mgHA/cm3)
• average bone density (Dtot; mgHA/cm3)
Bone structure
• trabecular bone volume to tissue volume (BV/TV; %)
• number of trabeculae (Tb.N; mm-1)
• trabecular thickness (Tb.Th; µm)
• trabecular separation (Tb. Sp; µm)
• cortical thickness (C.Th; µm)
• index of the inhomogeneity of the network (Tb.1/N.SD)
• cross-sectional area (CSA; mm2)Trials 2008, 9:19 http://www.trialsjournal.com/content/9/1/19
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measurements, and safety observations and measure-
ments.
To assess the treatment effects of calcitonin on bone
microarchitecture and provide a proof of concept, the pri-
mary analysis of the efficacy endpoints in this exploratory
trial will be based on the observed data of the per-protocol
population. Secondarily, an ITT analysis may be per-
formed to test the robustness of the results.
For each analyzed parameter a two-sided t-test will be
applied. The change from baseline between the two differ-
ent groups (active treatment/placebo) will be compared
by an analysis of covariance (ANCOVA) model with
change as the response variable, the baseline value as a
covariate, and treatment as a fixed factor.
The assessment of safety will be based mainly on the fre-
quency of adverse events and on the number of laboratory
values that fall outside of pre-determined ranges. Other
safety data (e.g. electrocardiogram, vital signs, special
tests) will be considered as appropriate.
Analysis of adverse events will be based on the safety pop-
ulation which includes all randomized patients who have
taken at least one dose of the study drug. Adverse events
will be summarized by presenting, for each treatment
group, the number and percentage of patients having any
adverse event, having an adverse event in each body sys-
tem and having each individual adverse event. Any other
information collected (e.g. severity or relatedness to study
medication) will be listed as appropriate.
Summary
This study will investigate the effects of nasal salmon cal-
citonin on bone microarchitecture and its relation with
markers of bone turnover in postmenopausal women. It
should thus give a new insight into the specific effects of
calcitonin on different bone parameters.
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